Novavax

YTD

ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines.

CEO

John C.s Jacobs

CEOJohn C.s Jacobs

Employees

749

Employees749

Headquarters

Gaithersburg, Maryland

HeadquartersGaithersburg, Maryland

Founded

1987

Founded1987

Employees

749

Employees749

NVAX Key Statistics

Market cap

1.78B

Market cap1.78B

Price-Earnings ratio

-23.10

Price-Earnings ratio-23.10

Dividend yield

—

Dividend yield—

Average volume

5.14M

Average volume5.14M

High today

$10.93

High today$10.93

Low today

$9.88

Low today$9.88

Open price

$10.06

Open price$10.06

Volume

6.29M

Volume6.29M

52 Week high

$13.39

52 Week high$13.39

52 Week low

$6.20

52 Week low$6.20

Stock Snapshot

Novavax(NVAX) stock is priced at $10.70, giving the company a market capitalization of 1.78B. It carries a P/E multiple of -23.10.

On 2026-11-07, Novavax(NVAX) stock traded between a low of $9.88 and a high of $10.93. Shares are currently priced at $10.70, which is +8.3% above the low and -2.1% below the high.

Novavax(NVAX) shares are trading with a volume of 6.29M, against a daily average of 5.14M.

In the last year, Novavax(NVAX) shares hit a 52-week high of $13.39 and a 52-week low of $6.20.

NVAX News

TipRanks 10h

Novavax Earnings Call Signals Stronger Growth Ahead

Novavax ((NVAX)) has held its Q3 earnings call. Read on for the main highlights of the call. Novavax’s earnings call carried a strongly positive tone, as partn...

Simply Wall St 16h

Novavax Stock Gets A Lift From Narrower Q3 Loss

Novavax reported third quarter 2026 revenue of US$68.3 million compared with US$70.45 million a year earlier, with net loss narrowing to US$31.38 million from U...

Zacks 20h

NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline

Novavax (NVAX Quick QuoteNVAX - Free Report) recorded a loss of 19 cents per share in the third quarter of 2026, narrower than the Zacks Consensus Estimat...

Analyst ratings

57%

of 7 ratings

Buy

57.1%

Hold

14.3%

Sell

28.6%

More NVAX News

Seeking Alpha 2d

Novavax gains after Q3 beat, guidance hike

Novavax (NVAX) shares rose in premarket trading on Thursday as the COVID-19 vaccine maker raised its full-year revenue outlook after delivering better-than-expe...

Simply Wall St 5d

What Is Driving Attention Around Novavax?

Novavax (NVAX) is back in focus after Sanofi’s Phase 3 influenza COVID-19 combination vaccine trial in the EU hit a dosing milestone, which triggered a US$125 m...

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.